When is TGTX's latest earnings report released?
The most recent financial report for Tg therapeutics, inc. (TGTX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TGTX's short-term business performance and financial health. For the latest updates on TGTX's earnings releases, visit this page regularly.
Where does TGTX fall in the P/E River chart?
According to historical valuation range analysis, Tg therapeutics, inc. (TGTX)'s current price-to-earnings (P/E) ratio is 10.75, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of TGTX?
According to the latest financial report, Tg therapeutics, inc. (TGTX) reported an Operating Profit of 50.49M with an Operating Margin of 26.22% this period, representing a growth of 136.17% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is TGTX's revenue growth?
In the latest financial report, Tg therapeutics, inc. (TGTX) announced revenue of 192.57M, with a Year-Over-Year growth rate of 92.79%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does TGTX have?
At the end of the period, Tg therapeutics, inc. (TGTX) held Total Cash and Cash Equivalents of 80.49M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does TGTX go with three margins increasing?
In the latest report, Tg therapeutics, inc. (TGTX) achieved the “three margins increasing” benchmark, with a gross margin of 80.2%%, operating margin of 26.22%%, and net margin of 12%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TGTX's profit trajectory and future growth potential.
Is TGTX's EPS continuing to grow?
According to the past four quarterly reports, Tg therapeutics, inc. (TGTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of TGTX?
Tg therapeutics, inc. (TGTX)'s Free Cash Flow (FCF) for the period is 19.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 89.98% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of TGTX?
The latest valuation data shows Tg therapeutics, inc. (TGTX) has a Price-To-Earnings (PE) ratio of 10.75 and a Price/Earnings-To-Growth (PEG) ratio of -0.49. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
